Scholarlink

<p>The landscape of oncology is undergoing a paradigm shift, transitioning from conventional cytotoxic therapies to an integrative, intelligence-driven framework that combines&#xa0;precision genomics, immunoengineering, and modulation of the tumor microenvironment (TME). This review explores how cancer, as a&#xa0;complex adaptive system (CAS), evolves through genetic, epigenetic, and microenvironmental interactions, necessitating dynamic, multi-dimensional therapeutic strategies. Review highlights the limitations of mono-targeted therapies and the emergence of&#xa0;synergistic approaches, including AI-guided adaptive dosing, synthetic biology-enhanced CAR-T cells, and metabolic reprogramming of the tumor microenvironment (TME). Breakthroughs in&#xa0;molecular cartography, quantum biology, synthetic oncology, and dark genome mining&#xa0;are expanding therapeutic frontiers. Meanwhile, immuno-engineering innovations–such as next-generation checkpoint modulators, logic-gated CAR-T cells, and neoantigen vaccines–are redefining immune-oncology. Additionally, TME-targeted strategies, including stromal remodeling, hypoxia modulation, and microbiome engineering, are helping to overcome treatment resistance. The convergence of&#xa0;multi-omics profiling, combinatorial therapeutics, and computational oncology (e.g., digital twins)&#xa0;is enabling real-time, personalized interventions. Despite these advances, challenges persist–therapeutic resistance, toxicity, accessibility, and ethical concerns–demanding interdisciplinary collaboration and equitable innovation. The future lies in&#xa0;adaptive, autonomous oncology, integrating AI, closed-loop therapies, and modular mRNA platforms to deliver precision medicine at scale. This review underscores the imperative for a&#xa0;unified, systems-based approach&#xa0;to transform cancer into a manageable condition.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Next-generation oncology: integrative therapeutic frontiers at the crossroads of precision genomics, immuno-engineering, and tumor microenvironment modulation

  • 期刊论文

  • 发表日期：

    2025年9月20日

查看全文
  • Ahmad M. Alamri,
  • Abdullah A. Assiri,
  • Bushra Khan,
  • Najeeb Ullah Khan

摘要

The landscape of oncology is undergoing a paradigm shift, transitioning from conventional cytotoxic therapies to an integrative, intelligence-driven framework that combines precision genomics, immunoengineering, and modulation of the tumor microenvironment (TME). This review explores how cancer, as a complex adaptive system (CAS), evolves through genetic, epigenetic, and microenvironmental interactions, necessitating dynamic, multi-dimensional therapeutic strategies. Review highlights the limitations of mono-targeted therapies and the emergence of synergistic approaches, including AI-guided adaptive dosing, synthetic biology-enhanced CAR-T cells, and metabolic reprogramming of the tumor microenvironment (TME). Breakthroughs in molecular cartography, quantum biology, synthetic oncology, and dark genome mining are expanding therapeutic frontiers. Meanwhile, immuno-engineering innovations–such as next-generation checkpoint modulators, logic-gated CAR-T cells, and neoantigen vaccines–are redefining immune-oncology. Additionally, TME-targeted strategies, including stromal remodeling, hypoxia modulation, and microbiome engineering, are helping to overcome treatment resistance. The convergence of multi-omics profiling, combinatorial therapeutics, and computational oncology (e.g., digital twins) is enabling real-time, personalized interventions. Despite these advances, challenges persist–therapeutic resistance, toxicity, accessibility, and ethical concerns–demanding interdisciplinary collaboration and equitable innovation. The future lies in adaptive, autonomous oncology, integrating AI, closed-loop therapies, and modular mRNA platforms to deliver precision medicine at scale. This review underscores the imperative for a unified, systems-based approach to transform cancer into a manageable condition.

Graphical Abstract